drugset / Trial / NCT04667299
Bismuth-Metronidazole Triple Therapy for H. Pylori First-line Treatment
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized controlled clinical trial will compare the eradication efficacy of bismuth-metronidazole triple therapy (PPI+bismuth+ metronidazole) with that of bismuth-metronidazole quadruple therapy (PPI+bismuth+ metronidazole+ amoxicillin) for Helicobacter pylori first-line treatment. The completion of this trial will expand new therapy for the treatment of Helicobacter pylori, which can not only ensure clinical efficacy, but also reduce the use of antibiotics.
Timeline
- Start
- 2020-12-20
- Primary completion
- 2021-11-20
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Amoxicillin | Other / unclassified | 1 g | — |
| Background | Bismuth Potassium Citrate | Unknown | 0.6 g | — |
| Background | Metronidazole | Small molecule | 0.4 g | — |
| Background | Rabeprazole | Small molecule | 20 mg | — |